Yahoo Web Search

Search results

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 9 minutes ago

      PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024

    • Small Business - The Brewton Standard | The Brewton Standard

      The Brewton Standard· 28 minutes ago

      Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in